Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
AstraZeneca said a clinical trial of its lung cancer treatment failed to meet its primary goal of improving survival rates compared with chemotherapy.
In the primary analysis population of patients whose blood tumour mutational burden was 20 or more mutations per megabase, the combination of AstraZeneca's Imfinzi and tremelimumab did not meet the primary endpoint of improving overall survival compared to standard of care chemotherapy, the company said.
The Neptune trial was a randomised, open-label, multi-centre, global, Phase III trial of Imfinzi in combination with tremelimumab versus standard of care platinum-based chemotherapy in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer.
'We are fully committed to a deep analysis of the vast clinical and biomarker data from this trial to gain further insights to improve Immuno-Oncology approaches for patients with metastatic non-small cell lung cancer,' said José Baselga, Executive Vice President, Oncology R&D.